PSMA PET may improve the diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole-mount histophathology

Positron emission tomography (PET) using novel ligands targeting prostate specific membrane antigen (PSMA) is becoming readily available in many parts of the world such as Australia, the United States of America, Germany, Italy, United Kingdom and Turkey. Using PSMA as a functional marker of malignant potential, this article explores the benefits and limitations of PSMA PET CT in detecting tumor foci within prostate. Read more.

Tags: Cancer PET Prostate Research

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap